# SEC Form 4

П

# FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Check this box if no longer subject to	)
Section 16. Form 4 or Form 5	
obligations may continue. See	
Instruction 1(b).	

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

## OMB APPROVAL OMB Number: 3235-0287

- 1		
	Estimated average burden	
	hours per response:	0.5
- 5		

1. Marile and Address of Reporting Ferson			2. Issuer Name and Ticker or Trading Symbol Evelo Biosciences, Inc. [EVLO]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)					
Epstem David	<u>1 R</u>		L	X	Director	10% Owner			
	(First) OSCIENCES, INC	(Middle)	3. Date of Earliest Transaction (Month/Day/Year) 09/14/2019		Officer (give title below)	Other (specify below)			
620 MEMORIAL DRIVE			4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Indiv Line)	lividual or Joint/Group Filing (Check Applicable				
(Street)				X	Form filed by One Rep	oorting Person			
CAMBRIDGE	MA	02139			Form filed by More tha Person	n One Reporting			
(City)	(State)	(Zip)							

### Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Year) Code (Instr. 5) 8)		(D) (Instr. 3, 4 and		5. Amount of Securities Beneficially Owned Following	(D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership
					(A) or (D)	Price	Reported Transaction(s) (Instr. 3 and 4)		(Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code ( 8)		5. Numb of Derivati Securiti Acquire (A) or Dispose of (D) (II 3, 4 and	ve es d ed nstr.	6. Date Exerc Expiration Da (Month/Day/Y	ate	7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Stock Option (Right to Buy)	\$7. <mark>93</mark>	09/14/2019		Α		75,000		(1)	09/13/2029	Common Stock	75,000	\$0	75,000	D	
Stock Option (Right to Buy)	\$7 <mark>.9</mark> 3	09/14/2019		A		75,000		(2)	09/13/2029	Common Stock	75,000	\$0	75,000	D	

#### Explanation of Responses:

1. Such option to vest and become exercisable in 36 equal monthly installments occurring upon Mr. Epstein's completion of each successive full month of service as the Chairman of the Board of Directors following the date of grant, provided that any share which would be fractionally vested shall be accumulated and shall vest on the first vesting date upon which the whole share has accumulated, and provided further that such option will vest in full upon a Change in Control (as defined in the Plan) that occurs prior to or at the time of Mr. Epstein's termination of service as the Chairman of the Board of Directors. 2. Such option to vest and become exercisable in 36 equal monthly installments occurring upon Mr. Epstein's completion of each successive full month of service as a consultant to the Company following the date of grant, provided that any share which would be fractionally vested shall be accumulated and shall vest on the first vesting date upon which the whole share has accumulated, and provided further that such option will vest in full upon a Change in Control that occurs prior to or at the time of Mr. Epstein's termination of service as a consultant to the Company.

Remarks:

#### /s/ Jonathan Poole, Attorney-in-09/17/2019

Fact for David R. Epstein

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.